Navigation Links
Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
Date:10/21/2008

Large-Scale Rapid Production, Increased Bioavailability

MOUNTAIN VIEW, Calif., Oct. 21 /PRNewswire/ -- An increased number of diseases that are either incurable or difficult to treat allures clinicians to the approach of stem cell therapy. Highly prized, due to their therapeutic potential, stem cell therapies are believed to treat a wide variety of diseases. Stem cell research progresses at a fast pace; however, both adult and embryonic stem cells have their own unique challenges that must be overcome before therapies make it to the market.

New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), U.S. Stem Cell Market - Current Developments, provides insights and analysis on stem cell therapeutic development in the U.S., including the clinical trial pipeline, key market drivers and challenges, and the market potential for stem cell therapy in selected disease indications. In this research, Frost & Sullivan's expert analysts thoroughly examine this cutting-edge healthcare technology market.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of U.S. Stem Cell Market - Current Developments, please send an e-mail to Johanna Haynes, Corporate Communications, at johanna.haynes@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

"New research into stem cell therapies has resulted in several technological innovations that have improved the manufacturing and design of these products," notes Frost & Sullivan Research Analyst Katheryn Symank. "For example, improvements in cell sorting and cell culture have allowed for improved survival and growth of adult stem cells. This allows for the rapid production of a high-quality adult stem cell product with increased bio-availability that may be produced on a large scale."

Adult stem cell therapies were traditionally thought to have poor therapeutic potential because they could only be produced in limited quantities or as needed. Now adult stem cells have the potential to become standardized pre-made therapies that can be mass produced.

However, both stem cell types have challenges and technical difficulties that impede product development. Embryonic stem cells, while hailed for their promise as potential therapies, are immersed in both political and ethical controversy. In addition, some researchers have questioned the safety of embryonic stem cells in humans, while adult stem cells require a high degree of technical expertise because they are difficult to culture and lose potency over time.

"Both embryonic stem cells and adult stem cells have their own challenges that must be overcome," explains Symank. "The controversy surrounding embryonic stem cells has resulted in severe limitations in federal funding for their research, while adult stem cells are often viewed as having less therapeutic potential because they can differentiate into a limited number of cells."

New evidence suggests that adult stem cells may actually have more plasticity than once thought, and may actually derive more tissue types. In addition, new technical innovations allow for adult stem cells to be cultured in large quantities without the loss of potency. In regards to embryonic stem cells, despite the severe limitations in federal funding, support from private sources and individual states have allowed research to progress at a fast pace. However, there have been concerns over the safety of the use of embryonic stem cells in humans because of potential adverse consequences from undifferentiated cells.

"In order to ensure the safety of embryonic stem cell products in humans, strict manufacturing regulations may need to be imposed by the FDA," advises Symank. "In addition, there could be strict product safety testing in place to guarantee their safety."

U.S. Stem Cell Market: Current Developments is part of the Pharmaceuticals and Biotechnology subscription, which also includes research in the following markets: Biopharmaceuticals, Specialty Pharmaceuticals, Contract Research and Manufacturing, Vaccines, and Drug Delivery. Recent titles include: U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market, U.S. Contract Research Outsourcing Market, European Biosimilars Market Outlook and U.S. Human Growth Hormone Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

Contact:

Johanna Haynes

Corporate Communications - North America

P: 210.247.3870

F: 210.348.1003

E: johanna.haynes@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
2. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
3. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. Atrium Innovations Announces Management Changes
6. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
7. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
8. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
9. Mediatech Moves to Prince William County Innovation Park
10. The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
11. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, ... study showed that aerosolized KL4 surfactant reduced lung ... preclinical animal model. The Company believes that these ... evidence that supports the role of KL4 surfactant ...
Breaking Biology Technology:
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
Breaking Biology News(10 mins):